Calculators

401k Retirement Calculator Mortgage Calculator

New

Student Loan Calculator Auto Loan Calculator

Education

How To Use TipRanks TipRanks Labs Webinar Center Glossary FAQs

About Us

About TipRanks TipRanks Community Contact Us Careers Reviews Mobile APP

Working with TipRanks

Enterprise Solutions Top Online Brokers Become an Affiliate

News Smart Portfolio Expert Center TipRanksAI

TOOLS

Daily Analyst Ratings

STOCKS

ADVANCED RESEARCH

Invest Like a Pro with Unique Data & Simplifed ToolsTry Now

Dividend Center

Best Dividend Stocks

Popular

Best High Yield Dividend Stocks

Dividend Aristocrats

Dividend Stock Comparison

New

Dividend Calculator

Dividend Returns Comparison

Dividend Calendar

Top Analysts

Top Financial Bloggers

Top-Performing Corporate Insiders

Top Hedge Fund Managers

Top Research Firms

Top Individual Investors

News

Portfolio

Personal Finance Center

Mortgages

Loans

Investing & Retirement

Spending & Savings

Calculators

Compound Interest Calculator

Student Loan Calculator

401k Retirement Calculator

Education

About Us

Working with TipRanks

Enterprise Solutions

Top Online Brokers

Become an Affiliate

IMGO

The FlyMerck completes tender offer to acquire Imago BioSciences

1y ago

MRK

IMGO

PremiumThe Fly

Imago BioSciences:1st participant dosed in bomedemstat/ruxolitinib study for MF

1y ago

IMGO

PremiumPress Releases

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis

1y ago

IMGO

PremiumThe Fly

Eight new option listings and one option delisting on December 14th

1y ago

CBNK

IMGO

PremiumPress Releases

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2022

1y ago

IMGO

PremiumThe FlyImago BioSciences presents data from Phase 2 study of bomedemstat in ET

1y ago

IMGO

PremiumThe Fly

Imago BioSciences presents data from ongoing Phase 2 study of bomedemstat

1y ago

IMGO

PremiumPress Releases

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022

1y ago

IMGO

PremiumThe Fly

Imago BioSciences says 1st patient dosed in bomedemstat combo study for AML

1y ago

IMGO

$Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia$

PremiumPress Releases

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

1y ago

IMGO

PremiumThe Fly

Imago BioSciences downgraded to Hold from Buy at Stifel

1y ago

IMGO

PremiumMarket News

Merck Snaps Up Imago for $1.35 Billion; Stock Up 100%

1y ago

MRK

IMGO

PremiumThe FlyImago BioSciences reports Q3 EPS (50c), consensus (44c)

1y ago

IMGO

PremiumPress Releases

Imago BioSciences Reports Third Quarter 2022 Financial Results and Provides Recent Business Updates

1y ago

IMGO

PremiumPress Releases

Imago BioSciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

2y ago

IMGO

PremiumPress Releases

Imago BioSciences to Participate in the 2022 Wedbush PacGrow Healthcare Conference

2y ago

IMGO

PremiumPress Releases

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at EHA 2022

2y ago

IMGO

PremiumPress Releases

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at EHA 2022

2y ago

IMGO

PremiumPress Releases

Imago BioSciences to Host Virtual Investor Event

2y ago

IMGO

IMGO

Trending

Indices

Stocks

ETFs